The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | The evolving field of rectal cancer management
Xavier Serra-Aracil, MD, PhD, Parc Tauli University Hospital, Barcelona, Spain, talks on the management of rectal cancer. Chemoradiotherapy and total mesorectal excision (TME) is the standard treatment for locoregional rectal cancer. However, with novel combinations of chemoradiotherapy, avoiding TME may be possible in the near future. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
